Quantitative Assessment of Population Variability in Hepatic Drug Metabolism Using a Perfused Three-Dimensional Human Liver Microphysiological System
2016/10/20 by Nikolaos Tsamandouras, N. Tsamandouras, Tomasz Kostrzewski +9 · 27 citations
Pharmacology, Toxicology and Pharmaceutics · Chemistry · Medicine · #Pharmacogenetics and Drug Metabolism #Analytical Chemistry and Chromatography #Drug Transport and Resistance Mechanisms
paper · pdf · doi:10.1124/jpet.116.237495
Abstract
In this work, we first describe the population variability in hepatic drug metabolism using cryopreserved hepatocytes from five different donors cultured in a perfused three-dimensional human liver microphysiological system, and then show how the resulting data can be integrated with a modeling and simulation framework to accomplish in vitro-in vivo translation. For each donor, metabolic depletion profiles of six compounds (phenacetin, diclofenac, lidocaine, ibuprofen, propranolol, and prednisolone) were measured, along with metabolite formation, mRNA levels of 90 metabolism-related genes, and markers of functional viability [lactate dehydrogenase (LDH) release, albumin, and urea production]. Drug depletion data were analyzed with mixed-effects modeling. Substantial interdonor variability was observed with respect to gene expression levels, drug metabolism, and other measured hepatocyte functions. Specifically, interdonor variability in intrinsic metabolic clearance ranged from 24.1% for phenacetin to 66.8% for propranolol (expressed as coefficient of variation). Albumin, urea, LDH, and cytochrome P450 mRNA levels were identified as significant predictors of in vitro metabolic clearance. Predicted clearance values from the liver microphysiological system were correlated with the observed in vivo values. A population physiologically based pharmacokinetic model was developed for lidocaine to illustrate the translation of the in vitro output to the observed pharmacokinetic variability in vivo. Stochastic simulations with this model successfully predicted the observed clinical concentration-time profiles and the associated population variability. This is the first study of population variability in drug metabolism in the context of a microphysiological system and has important implications for the use of these systems during the drug development process.
Citations
Cited by
- Integrated Assessment of Diclofenac Biotransformation, Pharmacokinetics, and Omics-Based Toxicity in a Three-Dimensional Human Liver-Immunocompetent Coculture System
- Human organs-on-chips for disease modelling, drug development and personalized medicine
- Multi-functional scaling methodology for translational pharmacokinetic and pharmacodynamic applications using integrated microphysiological systems (MPS). [europepmc]
- Integrated gut/liver microphysiological systems elucidates inflammatory inter-tissue crosstalk. [europepmc]
- Integrated Gut and Liver Microphysiological Systems for Quantitative In Vitro Pharmacokinetic Studies. [europepmc]
- Interconnected Microphysiological Systems for Quantitative Biology and Pharmacology Studies. [europepmc]
- Maximizing the impact of microphysiological systems with in vitro-in vivo translation. [europepmc]
- Progress, obstacles, and limitations in the use of stem cells in organ-on-a-chip models. [europepmc]
- Advances in Engineered Human Liver Platforms for Drug Metabolism Studies. [europepmc]
- Emerging Role of Organ-on-a-Chip Technologies in Quantitative Clinical Pharmacology Evaluation. [europepmc]
- Monitoring of Microphysiological Systems: Integrating Sensors and Real-Time Data Analysis toward Autonomous Decision-Making. [europepmc]
- Measuring and regulating oxygen levels in microphysiological systems: design, material, and sensor considerations. [europepmc]
- Liver Microphysiological Systems for Predicting and Evaluating Drug Effects. [europepmc]
- On the potential of in vitro organ-chip models to define temporal pharmacokinetic-pharmacodynamic relationships. [europepmc]
- A Microphysiological System for Studying Nonalcoholic Steatohepatitis. [europepmc]
- Engineered tissues and strategies to overcome challenges in drug development. [europepmc]
- Is it Time for Reviewer 3 to Request Human Organ Chip Experiments Instead of Animal Validation Studies? [europepmc]
- Human biomimetic liver microphysiology systems in drug development and precision medicine. [europepmc]
- Characterizing the reproducibility in using a liver microphysiological system for assaying drug toxicity, metabolism, and accumulation. [europepmc]
- A Critical Perspective on 3D Liver Models for Drug Metabolism and Toxicology Studies. [europepmc]
- 3D cell culture models: Drug pharmacokinetics, safety assessment, and regulatory consideration. [europepmc]
- Modelling human liver fibrosis in the context of non-alcoholic steatohepatitis using a microphysiological system. [europepmc]
- Studying metabolism with multi-organ chips: new tools for disease modelling, pharmacokinetics and pharmacodynamics. [europepmc]
- Human organs-on-chips for disease modelling, drug development and personalized medicine. [europepmc]
- Organs-on-Chips Platforms Are Everywhere: A Zoom on Biomedical Investigation. [europepmc]
- Microfluidic Liver-on-a-Chip for Preclinical Drug Discovery. [europepmc]
- Organ-on-a-chip meets artificial intelligence in drug evaluation. [europepmc]
Related
- Predictive In Vitro-In Vivo Extrapolation for Time Dependent Inhibition of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and CYP2D6 Using Pooled Human Hepatocytes, Human Liver Microsomes, and a Simple Mechanistic Static Model
- Integrated Assessment of Diclofenac Biotransformation, Pharmacokinetics, and Omics-Based Toxicity in a Three-Dimensional Human Liver-Immunocompetent Coculture System
- Physiologically‐Based Pharmacokinetic Models as Enablers of Precision Dosing in Drug Development: Pivotal Role of the Human Mass Balance Study
- Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
- In vitro hepatic metabolism input parameters support toxicokinetic simulations for the formation of methoxy propionic acid from β‐Isomer propylene glycol methyl ether